The results of the SOUL clinical trial have revealed a groundbreaking 14% reduction in Major Adverse Cardiovascular Events (MACE) with oral Semaglutide (Rybelsus). This includes significant prevention of cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke, marking a major advancement in diabetes care and cardiovascular risk reduction. We proudly acknowledge the invaluable contributions of trial participants and extend our heartfelt congratulations to all involved. It is an honor for our center to have played a pivotal role in this milestone study.